Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients

Clinical Transplantation

Volumn 23, Issue 6, 2009, Pages 887-896

  Rogers, Christin C ^a   Johnson, Scott R ^a   Mandelbrot, Didier A ^a   Pavlakis, Martha ^a   Horwedel, Timothy ^a   Karp, Seth J ^a   Egbuna, Ogo ^a   Rodrigue, James R ^b   Chudzinski, Robyn E ^a   Goldfarb Rumyantzev, Alexander S ^a   Hanto, Douglas W ^a   Curry, Michael P ^a  

^a Department of Pharmacy ^*  (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Calcineurin inhibitor nephrotoxicty; Calcineurin inhibitor withdrawal; Liver transplantation; Sirolimus

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANEMIA; ANGIONEUROTIC EDEMA; ARTERY THROMBOSIS; ARTICLE; AVASCULAR NECROSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DEPRESSION; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FACE RASH; FEMALE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATIC ARTERY THROMBOSIS; HUMAN; HYPERTRIGLYCERIDEMIA; INCISIONAL HERNIA; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUROTOXICITY; PANCYTOPENIA; PNEUMONIA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; VIRUS INFECTION; VIRUS SYNDROME; WOUND HEALING IMPAIRMENT; COMPARATIVE STUDY; CONVALESCENCE; DRUG EFFECTS; FOLLOW UP; GRAFT REJECTION; KIDNEY; MIDDLE AGED; PHYSIOLOGY; TIME; TREATMENT OUTCOME;

CALCINEURIN INHIBITORS; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 71149108685     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01040.x     Document Type: Article

References (28)

1. Ojo AO, Held PJ, Port FK. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931.
2. Gonwa TA, Mai ML, Melton LB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001, 72:1934.
3. [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals; 2009
4. Flechner SM, Goldfarb D, Solez K. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007, 83:883.
5. Shenoy S, Hardinger KL, Crippin J. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007, 83:1389.
6. Campbell MS, Rai J, Kozin E. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant 2007, 21:377.
7. Morard I, Dumortier J, Spahr L. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007, 13:658.
8. Maheshwari A, Torbenson MS, Thuluvath PJ. Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Dig Dis Sci 2006, 51:1677.
9. Montalbano M, Neff GW, Slapak-Green G, Berney T, Meyer D. Sirolimus therapy in orthotopic liver transplant (OLT) recipients with acute renal insufficiency. Dig Dis Sci 2004, 49:1986.
10. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003, 9:126.
11. Heffron TG, Smallwood GA, Davis L, Martinez E, Stieber AC. Sirolimus-based immunosuppressive [correction of immunosuppresive] protocol for calcineurin sparing in liver transplantation. Transplant Proc 2002, 34:1522.
12. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003, 9:1079.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461.
14. Foundation NK. K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002, 39(Suppl. 1):S1.
15. Miller BW. Chronic kidney disease in solid-organ transplantation. Adv Chronic Kidney Dis 2006, 13:29.
16. Sindhi R, Seward J, Mazariegos G. Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transplant 2005, 9:391.
17. Cotterell AH, Fisher RA, King AL. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002, 16(Suppl. 7):49.
18. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001, 7:384.
19. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998, 66:59.
20. Neff GW, Montalbano M, Slapak-Green G. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003, 35:3029.
21. Watson CJ, Gimson AE, Alexander GJ. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007, 13:1694.
22. Vivarelli M, Vetrone G, Zanello M. Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature. Transpl Int 2006, 19:1022.
23. Asfandiyar S, Abouljoud M, Kim D. Influence of hepatitis C on renal function after liver transplantation. Transplant Proc 2006, 38:3643.
24. Samonakis DN, Cholongitas E, Triantos CK. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005, 43:1091.
25. Zhu J, Wu J, Frizell E. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999, 117:1198.
26. Biecker E, De Gottardi A, Neef M. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 2005, 313:952.
27. McEwan P, Baboolal K, Conway P, Currie CJ. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. Clin Ther 2005, 27:1834.
28. McEwan P, Dixon S, Baboolal K, Conway P, Currie CJ. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics 2006, 24:67.